Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

<p>Related to Figure 2 - SMS-CTR</p>

Saved in:

书目详细资料
主要作者:	Katie E. Hebron (15046889) (author)
其他作者:	Xiaolin Wan (15046892) (author), Jacob S. Roth (15046895) (author), David J. Liewehr (15046898) (author), Nancy E. Sealover (15046901) (author), William J.E. Frye (15046904) (author), Angela Kim (15046907) (author), Stacey Stauffer (15046910) (author), Olivia L. Perkins (15046913) (author), Wenyue Sun (15046916) (author), Kristine A. Isanogle (15046919) (author), Christina M. Robinson (15046922) (author), Amy James (15046925) (author), Parirokh Awasthi (15046928) (author), Priya Shankarappa (15046931) (author), Xiaoling Luo (15046934) (author), Haiyan Lei (14963261) (author), Donna Butcher (15046937) (author), Roberta Smith (15046940) (author), Elijah F. Edmondson (14950075) (author), Jin-Qiu Chen (15046943) (author), Noemi Kedei (15046946) (author), Cody J. Peer (14946853) (author), Jack F. Shern (14938001) (author), W. Douglas Figg (15046949) (author), Lu Chen (15046952) (author), Matthew D. Hall (14938004) (author), Simone Difilippantonio (15046955) (author), Frederic G. Barr (15046958) (author), Robert L. Kortum (15046961) (author), Robert W. Robey (15046964) (author), Angelina V. Vaseva (14949310) (author), Javed Khan (15046967) (author), Marielle E. Yohe (15046970) (author)
出版:	2025
主题:	Cancer Therapeutic Research and Development Methods and Technology Drug Targets Cell surface receptor drug targets Protein kinase & phosphatase drug targets Pediatric Cancers Preclinical Models Animal models of cancer Translational Research
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
由: Srivandana Akshintala (16610490)
出版: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
由: Srivandana Akshintala (16610490)
出版: (2025)

Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
由: Clare F. Malone (14960925)
出版: (2025)

Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
由: Clare F. Malone (14960925)
出版: (2025)

Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
由: Clare F. Malone (14960925)
出版: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
由: Debarati Mukherjee (15134436)
出版: (2025)

Supplementary Video 2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
由: Debarati Mukherjee (15134436)
出版: (2025)

Supplementary Video 3 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
由: Debarati Mukherjee (15134436)
出版: (2025)

Supplementary Video 4 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
由: Debarati Mukherjee (15134436)
出版: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
由: Evan C. Chen (15054014)
出版: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
由: Evan C. Chen (15054014)
出版: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
由: Evan C. Chen (15054014)
出版: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
由: Evan C. Chen (15054014)
出版: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
由: Evan C. Chen (15054014)
出版: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
由: Evan C. Chen (15054014)
出版: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
由: Yuncheng Bei (16546095)
出版: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
由: Yuncheng Bei (16546095)
出版: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
由: Yuncheng Bei (16546095)
出版: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
由: Zev A. Wainberg (15047031)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_aombor61nku914v5ummepqq7v8